The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Childhood maltreatment is associated with a poor treatment response to conventional antidepressants and increased risk for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor (NDMAR) antagonist ketamine has been shown to rapidly improve symptoms of depression in patients with TRD. It is unknown if childhood maltreatment could influence ketamine’s treatment response. We examined the relationship between childhood maltreatment using the Childhood Trauma Questionnaire (CTQ) and treatment response using the Quick Inventory of Depressive Symptoms–Self Report (QIDS-SR) in TRD patients receiving intravenous ketamine at a community outpatient clinic. We evaluated treatment response after a single infusion (n = 115) and a course of repeated infusions (n = 63). Repeated measures general linear models and Bayes factor (BF) showed significant decreases in QIDS-SR after the first and second infusions, which plateaued after the third infusion. Clinically significant childhood sexual abuse, physical abuse, and cumulative clinically significant maltreatment on multiple domains (maltreatment load) were associated with better treatment response to a single and repeated infusions. After repeated infusions, higher load was also associated with a higher remission rate. In contrast to conventional antidepressants, ketamine could be more effective in TRD patients with more childhood trauma burden, perhaps due to ketamine’s proposed ability to block trauma-associated behavioral sensitization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, prelimi nary evidence suggests that response to vortioxetine or ketamine treatment in depression is not reduced in persons with trauma, suggesting different outcomes as a function of the putative mechanism of action of medi cations 126,127 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [127]
The cited source says what the claim attributes to it.
In the citing paper
“The attenuated response to antidepressants in persons with a history of childhood maltreatment may not, however, occur with all antidepressants.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Initial reliability and validity of a new retrospective measure of child abuse and neglect
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1132 · Cited by 3,577 · cited 3×
“The CTQ [41,42] is a 28-item self-report scale measuring childhood maltreatment prior to the age of 18.”
MethodBardo, M. T., & Hammer, R. P. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90226-e · Cited by 3,219
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 3×
“2% of US residents 13 years and older have a lifetime history of recurring major depressive episodes associated with major depressive disorder (MDD) or bipolar disorder (BD) [1].”
BackgroundInfluentialKalivas, P. W., & Stewart, J. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,019
Bayesian inference for psychology. Part II: Example applications with JASP
Wagenmakers, E.-J., Love, J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Selker, R., Gronau, Q. F., Dropmann, D., Boutin, B., et al. (2018) · Psychonomic Bulletin & Review · doi:10.3758/s13423-017-1323-7 · Cited by 1,715
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480 · cited 2×
“A history of childhood maltreatment has been associated with a diminished treatment response to conventional antidepressant treatments [17].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Weight based dosing of IV ketamine was delivered over 40 min–2 h as per standard procedures described in numerous publications [6,43].”
MethodSelf-citationBaldwin, J. R., Reuben, A., Newbury, J. B., & Danese, A. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0097 · Cited by 1,094 · cited 1×
“It is also a retrospective measure, which may be affected by recall bias, with patients either minimizing or exaggerating actual maltreatment [40].”
BackgroundTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
Wolf, M. E. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00090-7 · Cited by 934
Childhood maltreatment and characteristics of adult depression: Meta-analysis
Nelson, J., Klumparendt, A., Doebler, P., & Ehring, T. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.180752 · Cited by 822 · cited 1×
“A risk factor for TRD in adulthood is maltreatment in early life [17,18].”
BackgroundSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Self-citationFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613 · cited 2×
“No information to our knowledge is available regarding the relationship between childhood maltreatment and ketamine treatment response, although there is emerging support for the efficacy of IV ketamine in reducing symptoms of PTSD in adults [20,21].”
BackgroundSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
The Prevalence of Confirmed Maltreatment Among US Children, 2004 to 2011
Wildeman, C., Emanuel, N., Leventhal, J. M., Putnam-Hornstein, E., Waldfogel, J., & Lee, H. (2014) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2014.410 · Cited by 487 · cited 1×
“5% of US children and adolescents have been exposed to sexual abuse, physical abuse or neglect, or emotional abuse or neglect [19].”
BackgroundKetamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455 · cited 12×
“The N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine is a promising treatment option for TRD [5].”
BackgroundInfluential(2007) · PubMed · Cited by 453
Costs of Health Care Use by Women HMO Members With a History of Childhood Abuse and Neglect
Walker, E. A., Unutzer, J., Rutter, C., Gelfand, A., Saunders, K., VonKorff, M., Koss, M. P., & Katon, W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.7.609 · Cited by 446 · cited 2×
“Following previously established guidelines, clinically significant maltreatment in each domain is defined as a score of at least 8 (sexual abuse, physical abuse, physical neglect), 10 (emotional abuse), and 15 (emotional neglect) [24].”
MethodQuintana, D. S., & Williams, D. R. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1761-4 · Cited by 408
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390 · cited 1×
“Ketamine’s antidepressant effect has been related to pre- and post-synaptic NMDAR blockade, enhancing prefrontal [10] and hippocampal [11] glutamate concentrations which activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), enhancing synaptic plasticity via AMPAR-induced elevation of brai…”
BackgroundMcGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Kalivas, P. W., & Alesdatter, J. E. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39530-3 · Cited by 367
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321 · cited 1×
“Compared to treatment responders, TRD is associated with a lower quality of life and increased mortality [3,4].”
BackgroundMarsman, M., & Wagenmakers, E.-J. (2017) · European Journal of Developmental Psychology · doi:10.1080/17405629.2016.1259614 · Cited by 267
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253 · cited 1×
“Ketamine’s antidepressant effect has been related to pre- and post-synaptic NMDAR blockade, enhancing prefrontal [10] and hippocampal [11] glutamate concentrations which activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), enhancing synaptic plasticity via AMPAR-induced elevation of brai…”
BackgroundSelf-citationGarcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Stertz, L., Kapczinski, F., Gavioli, E. C., & Quevedo, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.01.004 · Cited by 237 · cited 2×
“In preclinical models, NMDAR antagonists blocked induction [38] and expression [31] of behavioral sensitization by stress, and in humans with PTSD, a subanesthetic dose of ketamine [20,21] or NMDR antagonist memantine [39] could improve symptoms of hyperarousal and depressive symptoms which are considered expressions…”
BackgroundThe effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
Abdallah, C. G., De Feyter, H. M., Averill, L. A., Jiang, L., Averill, C. L., Chowdhury, G. M. I., Purohit, P., de Graaf, R. A., Esterlis, I., Juchem, C., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0136-3 · Cited by 229 · cited 1×
“Ketamine’s antidepressant effect has been related to pre- and post-synaptic NMDAR blockade, enhancing prefrontal [10] and hippocampal [11] glutamate concentrations which activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), enhancing synaptic plasticity via AMPAR-induced elevation of brai…”
BackgroundWolf, M., White, F., & Hu, X. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-03-01735.1994 · Cited by 202
McLaughlin, K. A., Koenen, K. C., Bromet, E. J., Karam, E. G., Liu, H., Petukhova, M., Ruscio, A. M., Sampson, N. A., Stein, D. J., Aguilar-Gaxiola, S., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.197640 · Cited by 201
Kalivas, P. W. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)01063-q · Cited by 190
The role of mTOR in depression and antidepressant responses
Abelaira, H. M., Réus, G. Z., Neotti, M. V., & Quevedo, J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.02.014 · Cited by 186 · cited 1×
“Ketamine’s antidepressant effect has been related to pre- and post-synaptic NMDAR blockade, enhancing prefrontal [10] and hippocampal [11] glutamate concentrations which activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), enhancing synaptic plasticity via AMPAR-induced elevation of brai…”
BackgroundAlbott, C. S., Lim, K. O., Forbes, M. K., Erbes, C., Tye, S. J., Grabowski, J. G., Thuras, P., Batres-y-Carr, T. M., Wels, J., & Shiroma, P. R. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11634 · Cited by 159 · cited 2×
“No information to our knowledge is available regarding the relationship between childhood maltreatment and ketamine treatment response, although there is emerging support for the efficacy of IV ketamine in reducing symptoms of PTSD in adults [20,21].”
BackgroundMeta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.032 · Cited by 151
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors, J., Andersson, T. M.-L., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hägg, D., Wingård, L., & Bodén, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.030 · Cited by 94 · cited 10×
“Outcomes showed the significant effect of time, and a significant time by PA interaction (F[4, 236] = 5.”
BackgroundMethodInfluentialYap, J. J., Covington, H. E., Gale, M. C., Datta, R., & Miczek, K. A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2023-3 · Cited by 82 · cited 1×
“In preclinical models, NMDAR antagonists blocked induction [38] and expression [31] of behavioral sensitization by stress, and in humans with PTSD, a subanesthetic dose of ketamine [20,21] or NMDR antagonist memantine [39] could improve symptoms of hyperarousal and depressive symptoms which are considered expressions…”
BackgroundFreeman, M. P., Papakostas, G. I., Hoeppner, B., Mazzone, E., Judge, H., Cusin, C., Mathew, S., Sanacora, G., Iosifescu, D., DeBattista, C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.010 · Cited by 69 · cited 1×
“Although women had higher QIDS-SR scores than men irrespective of treatment, we found no evidence of different treatment responses between men and women, extending the lack of gender effects reported in controlled clinical trials using single dose infusion [26] to a clinical setting.”
BackgroundSelf-citationHoekstra, R., Monden, R., van Ravenzwaaij, D., & Wagenmakers, E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195474 · Cited by 57
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.12.009 · Cited by 54 · cited 1×
“Weight based dosing of IV ketamine was delivered over 40 min–2 h as per standard procedures described in numerous publications [6,43].”
MethodSelf-citationPilot Trial of Memantine in the Treatment of Posttraumatic Stress Disorder
Battista, M. A., Hierholzer, R., Khouzam, H. R., Barlow, A., & O'Toole, S. (2007) · Psychiatry: Interpersonal and Biological Processes · doi:10.1521/psyc.2007.70.2.167 · Cited by 47 · cited 1×
“In preclinical models, NMDAR antagonists blocked induction [38] and expression [31] of behavioral sensitization by stress, and in humans with PTSD, a subanesthetic dose of ketamine [20,21] or NMDR antagonist memantine [39] could improve symptoms of hyperarousal and depressive symptoms which are considered expressions…”
BackgroundThe role of MK-801 in sensitization to stimulants
Sripada, S., Gaytan, O., Swann, A. C., & Dafny, N. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00046-1 · Cited by 37 · cited 1×
“Induction and expression of behavioral sensitization require activation of N-methyl-D-aspartate receptors (NMDARs) [31,32] albeit via different neural pathways [33–37].”
BackgroundSelf-citationChen, J., Liang, K.-W., Huang, Y.-K., Liang, C.-S., & Chiang, Y. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)00995-4 · Cited by 34
Lijffijt, M., O'Brien, B., Salas, R., Mathew, S. J., & Swann, A. C. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0132 · Cited by 14 · cited 2×
“All statistical analyses were performed in JASP 0.9.0.1 [45].”
MethodInfluentialSelf-citationHoekstra, R., Monden, R., van Ravenzwaaij, D., & Wagenmakers, E. (2018) · doi:10.31234/osf.io/sdu63 · Cited by 5
Swann, A. C. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780199367894.003.0001 · Cited by 1
Self-citation
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Teicher, M. H., Gordon, J. B., & Nemeroff, C. B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01367-9 · Cited by 325
“[33] recently reported that participants with refractory depression and CM had a substantially better response to intravenous ketamine than refractory depressed individuals without CM.”
BackgroundGáll, Z., Farkas, S., Albert, Á., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2020) · Biomolecules · doi:10.3390/biom10050801 · Cited by 101
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
Self-citation
Metadata
- Authors
- O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Lone Star Infusion, PLLC, Houston, TX 77079, USA
- Corresponding author
- O’Brien, Brittany
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 12
- Issue
- 3
- Pages
- 133
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789614
- OpenAlex
- W2972990098
- Cited by
- 33
- References
- 47
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 3
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- child abuse, treatment-resistant depression, intravenous ketamine, child sexual abuse, physical abuse, remission, NMDA receptor antagonists, antidepressant response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.